Grape Seed Procyanidins in Pre- and Mild Hypertension: A Registry Study

Table 1

Key parameters at inclusion, 4, 8, 12, and 16 weeks.

Time

Systolic pressure

Diastolic pressure

Laser Doppler flux

Heart rate

Plasma-free radicals

Enovita 300 mg

Enovita 150 mg

Control

Enovita 300 mg

Enovita 150 mg

Control

Enovita 300 mg

Enovita 150 mg

Control

Enovita 300 mg

Enovita 150 mg

Control

Enovita 300 mg

Enovita 150 mg

Control

Inclusion

149; 4.5

150; 3

153.3; 4.4

91; 3.2

91.3; 2

90.4; 2.5

1.1; 0.01

1.1; 0.2

1.1; 0.01

78; 3.5

77.3; 4

77.2; 3.3

378; 22

382; 21

383; 23

4 weeks

121.3; 5.4^*#

129; 2.2^*#

142.3; 5*

86.3; 3.9*

88; 2*

88.4; 3*

1.28; 0.01^*#

1.2; 0.1

1.16; 0.01

73; 2.2*

73; 3.2*

74; 3.2*

—

—

—

8 weeks

119; 4.9^*#

125; 3^*#

142; 3.9

84.4; 2.8^*#

86.1; 2.1*

87; 3.6

2.13; 0.1^*#

1.6; 0.2^*#

1.22; 0.1

71; 3.1*

73; 2.1

74; 3.1

324; 19^*#

339; 32^*#

376; 29*

12 weeks

113; 3.3^*#

122; 3.2^*#

139; 3.5

83; 3.3^#

86.3; 2^#

88; 2.2

2.22; 0.2^*#

1.9; 0.2^*#

1.3; 0.1

69; 2.3*

72.2; 2^#

74; 2.3

—

—

—

16 weeks

112; 3.5^*#

123; 2.1^*#

141; 4.3

82.3; 3^#

85.3; 2^#

88.9; 3.2

2.23; 0.1^#

1.9; 0.2^#

1.2; 0.1

70; 1.5

72; 2.3

73.2; 2.2

317; 22^*#

342; 28^#

374; 22

^∗(𝑃<0.05) indicates statistical variations in comparison with previous value.
#: better than controls.